NeuroSense Therapeutics Ltd. (NRSNW) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Jul 23Jul 29Aug 3Aug 13Aug 18Aug 25Aug 31Sep 3

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.1x

Market Cap

$1.27M

MomentumView details →

1D Return

+0.00%

YTD Return

−85.16%

RSI (14)

44.7

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.1x

Market Cap

$1.27M

RSI (14)

44.7

MomentumView details →

1D Return

+0.00%

YTD Return

−85.16%

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

713.14%

ROA (TTM)

−1082.20%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+24.60%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

+20.00%

EBITDA YoY

−43.61%

EarningsView details →

EPS (Actual)

−$0.20

EPS Surprise

0.00%

Beats (12Q)

2/12

Next Q EPS Est

−$0.04

Avg Surprise (4Q)

−46.33%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

−0.11x

Current Ratio

0.31x

Quick Ratio

0.31x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−11.13M

Op. CF (TTM)

−3.67M

Next earningsDec 2, 2026 →

Latest newsMore news →

NeuroSense Therapeutics announced a redesigned, capital-efficient development strategy for its ALS drug PrimeC, including an AI-enabled formulation characterization, a comparative study against edaravone, and an optimized Phase 3 PARAGON trial design, with a New Drug Submission to Health Canada targeted for December 2026.1d ago

NeuroSense Therapeutics completed the pre-NDS process with Health Canada for its ALS drug PrimeC, receiving final meeting minutes that align on the planned submission content and structure, and is advancing toward a December 2026 filing.29d ago

Similar companies

YD Bio Limited WarrantsYDESW Scinai Immunotherapeutics Ltd.SCNI Abpro CorporationABP Iterum Therapeutics plcITRM Liminatus Pharma, Inc. WarrantsLIMNW Hepion Pharmaceuticals, Inc.HEPA Find similar companies →

Latest newsMore news →

NeuroSense Therapeutics announced a redesigned, capital-efficient development strategy for its ALS drug PrimeC, including an AI-enabled formulation characterization, a comparative study against edaravone, and an optimized Phase 3 PARAGON trial design, with a New Drug Submission to Health Canada targeted for December 2026.1d ago NeuroSense Therapeutics completed the pre-NDS process with Health Canada for its ALS drug PrimeC, receiving final meeting minutes that align on the planned submission content and structure, and is advancing toward a December 2026 filing.29d ago NeuroSense Therapeutics achieved the primary endpoint in a Phase 2b ALS study with PrimeC, showing statistically significant reduction of TDP-43.67d ago